Guselkumab
- Generic Name
- Guselkumab
- Brand Names
- Tremfya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350289-85-8
- Unique Ingredient Identifier
- 089658A12D
- Background
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptoma...
- Indication
Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 196
- Registration Number
- NCT06663332
- Locations
- 🇪🇸
Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain
Efficacy of Guselkumab in Treating Hailey Hailey Disease
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT06651489
- Locations
- 🇺🇸
Church Street Research Unit, Yale Center for Clinical Investigation, New Haven, Connecticut, United States
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT06586281
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 17
- Registration Number
- NCT06563323
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06408935
- Locations
- 🇨🇦
Western University & London Health Sciences Centre, London, Ontario, Canada
🇩🇪Charite Universitatsmedizin Berlin, Berlin, Germany
🇩🇪Medizinisches Versorgungszentrum (MVZ) Dachau, Dachau, Germany
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 338
- Registration Number
- NCT06039189
- Locations
- 🇺🇸
Suzanne Bruce and Associates - The Center for Skin Research, Houston, Texas, United States
🇺🇸Total Dermatology, Birmingham, Alabama, United States
🇺🇸Practice Wang, Riverside, California, United States
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05923073
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇧🇷Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro, Curitiba, Brazil
Immune Spatial Features of Guselkumab Cutaneous Response
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT05858632
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT05784129
- Locations
- 🇺🇸
Gastro Health Ohio, Cincinnati, Ohio, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 150
- Registration Number
- NCT05669833
- Locations
- 🇺🇸
Family Arthritis Center, Loxahatchee Groves, Florida, United States
🇺🇸Healing Rheumatology, Plant City, Florida, United States
🇺🇸Southwest Florida Rheumatology, Riverview, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.